Grants per year
Personal profile
Biography
An accomplished physician scientist, educator, and entrepreneur Fred Ledley is the author of >200 research papers in fields ranging from genetic medicine, cell biology, and biotechnology to strategic drug development and the financing of pharmaceutical innovation.
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Education/Academic qualification
Genetics, Clinical fellow, Boston Children's Hospital/Harvard Medical School
… → 1983
Molecular biology, Post-doctoral fellowship, Massachusetts Institute of Technology/American Cancer Society
… → 1983
Pediatrics, Intern/Resident, Boston Children's Hospital/Harvard Medical School
… → 1981
M.D., Georgetown University
… → 1978
Physical Science, B.S., University of Maryland
… → 1974
Fingerprint
Dive into the research topics where Fred Ledley is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Grants
- 5 Finished
-
Role of the NIH in drug development and public-private partnerships
Ledley, F. (Other)
National Pharmaceutical Council
01/1/21 → 12/31/22
Project: Research
-
Modeling the impact of changes in drug pricing policies and NIH funding on pharmaceutical innovation
Ledley, F. (Other) & Vaughan, G. (Other)
01/1/20 → 12/31/21
Project: Research
-
) Characterizing the public sector contribution to drug discovery and development
Ledley, F. (Other)
Institute for New Economic Thinking
01/1/20 → 12/31/20
Project: Research
-
Center forIntegration of Science and Industry
Ledley, F. (Other)
National Biomedical Research Foundation
04/1/12 → 06/30/25
Project: Research
-
-
Can Nonprofits Rectify the Failure to Develop Drugs for Diseases of Poverty?
Ledley, F., 2025Research output: Other contribution
-
Mergers and acquisitions (M&As) in pharmaceutical markets: associations with market concentration, prices, drug quantity sold, and shortages.
Ledley, F., 2025, (Accepted/In press)Research output: Other contribution
-
Modeling impact of inflation reduction act price negotiations on new drug pipeline considering differential contributions of large and small biopharmaceutical companies
Vaughan, G., Du, R. & Ledley, F., 2025, In: Unknown journal. 22, 1, p. 88-99Research output: Contribution to journal › Article
-
Sustaining pharmaceutical innovation after the Inflation Reduction Act: trends in R&D spending, equity investment, and business development
Dao, H. & Ledley, F., 2025, In: Unknown journal. 30, 7, p. 104394Research output: Contribution to journal › Article
-
Association between expedited review designations and the US or global burden of disease for drugs approved by the US Food and Drug Administration, 2010--2019: a cross-sectional analysis
Jackson, M. J., Vaughan, G. & Ledley, F., 2024, In: BMJ open. 14, 3, p. e076542Research output: Contribution to journal › Article